Healthcare [ 5/13 ] | Biotechnology [ 44/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 6, 24 | -1.24 Decreased by -217.95% | -0.82 Decreased by -51.22% |
| Nov 29, 23 | -1.02 Decreased by -25.93% | -0.6 Decreased by -70% |
| Aug 7, 23 | -0.96 Decreased by -41.18% | -0.65 Decreased by -47.69% |
| May 2, 23 | 0.45 Increased by +9.76% | -0.64 Increased by +170.31% |
| Feb 6, 23 | -0.39 Increased by +35% | 0.44 Decreased by -188.64% |
| Nov 28, 22 | -0.81 Decreased by -32.79% | -0.17 Decreased by -376.47% |
| Aug 4, 22 | -0.68 Decreased by -134.48% | -0.51 Decreased by -33.33% |
| May 10, 22 | 0.41 Increased by +257.69% | -0.08 Increased by +612.5% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 3.55 M Decreased by -94.32% | -132.86 M Decreased by -217.77% | Decreased by -3.74 K% Decreased by -5.5 K% |
| Sep 30, 23 | 16.1 M Decreased by -49.02% | -109.68 M Decreased by -27.62% | Decreased by -681.36% Decreased by -150.33% |
| Jun 30, 23 | 15.82 M Decreased by -51.18% | -102.95 M Decreased by -44.62% | Decreased by -650.53% Decreased by -196.21% |
| Mar 31, 23 | 146.27 M Decreased by -3.65% | 48.67 M Increased by +9.71% | Increased by +33.28% Increased by +13.87% |
| Dec 31, 22 | 62.55 M Increased by +127.95% | -41.81 M Increased by +33.5% | Decreased by -66.85% Increased by +70.83% |
| Sep 30, 22 | 31.57 M Decreased by -17.52% | -85.94 M Decreased by -35.61% | Decreased by -272.18% Decreased by -64.42% |
| Jun 30, 22 | 32.41 M Decreased by -29.37% | -71.18 M Decreased by -137.88% | Decreased by -219.62% Decreased by -236.8% |
| Mar 31, 22 | 151.81 M Increased by +362.66% | 44.37 M Increased by +265.43% | Increased by +29.23% Increased by +135.76% |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.